Immunity fades rapidly for some infections (influenza) but lasts a lifetime with others (measles). Here's what we know about COVID.
Academic rigour, journalistic flair
Articles on COVID vaccines
Displaying 1 - 20 of 55 articles
Italy's decision to block export of AstraZeneca vaccines to Australia will likely not impact our vaccine roll-out. But vaccine scarcity is a looming problem in other parts of the world.
South Africa is aiming for 67% coverage, which translates to about 40 million people by the end of 2021.
Most of us don't know yet when or where we'll receive our COVID vaccination. But particularly as there's a risk of scams, it's important to be clear on how this process will (and won't) play out.
In a digital age, and with unequal access to vaccines, there are considerable potential downsides to so-called 'vaccine passports'.
Our new research found gaps in COVID information available to culturally and linguistically diverse communities. But there are ways we can improve — because community ownership is crucial.
To make sure the COVID rollout is accessible to all people living in Australia, the government should consider a migrant amnesty.
Two residents in a Brisbane aged-care home were given a higher dose of the Pfizer vaccine than recommended. Here's what might have happened – and how we can reduce the risk it will happen again.
Australia's keenly awaited COVID vaccine rollout begins today. So how will it work, and will the vaccine be the end of all our coronavirus-related problems?
Some evidence suggests the immune response to asthma may offer some protection against COVID.
Facebook's decision to ban media organisations from posting links to news articles on the social media giant's platform comes under a week before Australia's COVID vaccine rollout begins.
When people start to hear that global case numbers are improving, there's a tendency to relax — and that's risky.
How will governments convince enough people to get vaccinated to achieve herd immunity?
Australia should pivot to a high-efficacy vaccine like Pfizer or Novavax to give us the best chance of achieving herd immunity.
Over 130 million doses have already been administered worldwide. It's early days, but the signs are promising in places like Israel and the UK.
These variants are definitely cause for concern. But there's every indication we can adapt our vaccine strategy to combat these and other variants going forward.
Giving money to support local production of COVID-19 vaccines is a step in the right direction if it will help in resuscitating Nigeria's vaccine production laboratory.
Vaccines should be seen as a kind of foreign aid.
After a dispute with AstraZeneca, the European Commission is restricting access to vaccines made within its borders.
It's going to be a huge logistical challenge.
Top contributors
-
Associate professor, UNSW
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Professor of Veterinary Microbiology, University of Ibadan
-
Researcher, Walter and Eliza Hall Institute
-
Associate professor, La Trobe University
-
Lecturer, Media and Communication, UWA, University of Western Australia
-
Reader in Health Economics, Centre for Health Economics, University of York
-
Professor in Global Public Health and Director of the Mitchell Institute, Victoria University
-
Lecturer, University of Technology Sydney
-
Senior Lecturer, University of Western Australia
-
Professor in Infectious Diseases Epidemiology, Monash University
-
Professor of Global Biosecurity, NHMRC Principal Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW
-
Professor of Immunology and Associate Provost, Research Partnerships, Victoria University
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
